Objective-The T-cell receptor zeta (TCR)-chain is a master sensor and regulator of lymphocyte responses. Loss of TCR-chain expression has been documented during infectious and inflammatory diseases and defines a population of effector T cells (TCR dim T cells) that migrate to inflamed tissues. We assessed the expression and functional correlates of circulating TCR dim T cells in coronary artery disease. Methods and Results-We examined the expression of TCR-chain by flow cytometry in 140 subjects. Increased peripheral blood CD4 ϩ TCR dim T cells were found in patients with acute coronary syndromes (ACS, nϭ66; median 5.3%, interquartile 2.6 to 9.1% of total CD4 ϩ T cells; PϽ0.0001) compared to chronic stable angina (CSA, nϭ32; 1.6%; 1.0 to 4.1%) and controls (nϭ42; 1.5%; 0.5 to 2.9%). Such increase was significantly greater in ACS patients with elevated levels of C-reactive protein, and it persisted after the acute event. Moreover, TCR dim cells were also more represented within CD8 ϩ T cell, NK, and CD4 ϩ CD28 null T cell subsets in ACS compared to CSA and controls. Finally, CD4
I
nflammation plays a key role in the pathogenesis of atherosclerosis with participation of both innate and adaptive immunity. [1] [2] [3] Upregulation of proinflammatory cytokines is common in acute coronary syndromes (ACS). 4 Elevated C-reactive protein (CRP) levels are associated with an adverse prognosis in patients with coronary artery disease (CAD), and healthy subjects. 4 The activation of inflammatory pathways in ACS is not confined to coronary lesions but involves the activation of neutrophils, monocytes, and lymphocytes in peripheral blood. [5] [6] [7] Most T cells found in human atherosclerotic lesions exhibit an effector or memory phenotype with a Th1 bias, and a predominance of CD4 ϩ over CD8 ϩ T cells. 8 Different subsets of T cells may drive or regulate inflammation during evolution of the atherosclerotic process, as in other inflammatory diseases. 9 An increased prevalence of specific circulating T cell subsets, such as CD4 ϩ CD28 null T cells, was reported in patients with ACS, as well as in patients with rheumatoid arthritis. 10 -13 The TCR-chain (CD247 or CD3) is a transmembrane protein with a small extracellular domain and an intracellular domain containing 3 immunoreceptor tyrosine-based activation motifs. The TCR-chain subunit associates with the TCR-CD3 complex as a homodimer, and couples antigen recognition by the TCR to downstream intracellular signaltransduction pathways through phosphorylation and recruitment of downstream proteins. The TCR-chain is also expressed in NK cells, where it is associated with the FcR␥III low affinity IgG receptor (CD16) and other activating receptors. 14 TCR-chain is therefore a master regulator and sensor of innate as well as adaptive immune responses, and so it follows from this that aberrations in its expression or function should be expected to have profound effects on immune function. 15 A subset of T cells expressing low levels of TCR-chain (hereafter TCR dim T cells) has been described in association with infectious, malignant, and inflammatory diseases. 14 -18 Downregulation of the TCR-chain, known to occur after antigen engagement or in response to inflammatory stimuli, may represent an attempt to modulate the immune response. 14 However, we previously reported that the TCR dim T-cell subset, although refractory to TCR-induced proliferation, 19 paradoxically displays features of antigen-experienced effector T cells. 15 Cell surface markers and tetramer analysis revealed that TCR dim T-cells are enriched for memory CD45RO ϩ cells, and for cells that had previously engaged antigen. Moreover, TCR dim T cells produce high levels of interferon (IFN) ␥ and tumor necrosis factor (TNF) ␣, and low levels of interleukin (IL)-10. 15 Finally, TCR dim T-cells display effector functions, eg, they can activate monocytes via cell contact-dependent pathways, and preferentially accumulate in inflamed tissues such as the rheumatoid joint. 15 In the present study we report that the frequencies of subsets of T cells and NK cells expressing low levels of TCR-chain are increased in patients with ACS when compared to patients with stable atherosclerotic lesions or to controls, particularly in patients with elevated levels of CRP, and remain elevated after the acute coronary event. TCR dim T cells display an enhanced ability to migrate through activated endothelium in vitro. Our findings suggest the possibility that antigen experienced T cells, defined by the TCR dim phenotype, may contribute to the inflammatory process that triggers coronary instability by accumulating in coronary plaques.
Methods

Study Population
Institutional Ethics Committees approved the study, and informed consent was obtained from all participating subjects. Venous peripheral blood samples were obtained from all patients on admission to San Raffaele Scientific Institute. Three groups participated in the study. Control group comprised 42 individuals with negative history, clinical, and electrocardiographic signs of CAD. CSA group included 32 patients with effort angina (lasting more than 3 months and without previous history of unstable angina or myocardial infarction) with angiographic evidence of coronary artery stenosis (stenosis Ͼ50% diameter). ACS group comprised 66 patients with chest pain accompanied by ischemic electrocardiographic changes (STsegment changes or T-wave inversions) or ST-segment elevation Ͼ2 mm in at least 2 consecutive leads associated to increase of troponin I. All samples were obtained on admission. Evidence of coronary artery stenosis/occlusion was documented by coronary angiography. Exclusion criteria included recent surgery, documented immune, infectious or neoplastic disease, immunosuppressive therapy, ACS attributable to intrastent thrombosis, or occlusion of arterious and venous by-pass grafts (confirmed after angiography). In 17 patients with ACS the levels of TCR-chain were also assessed after a 50-day median time (interquartile 39 to 83 days) from admission. Further analysis of TCR-chain expression was performed in CD8 ϩ T and NK cells (14 control, 9 CSA and 22 ACS participating in the study) and in CD4 ϩ CD28 null T cells (19 controls, 18 CSA and 23 ACS).
Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were purified by Ficoll-Hypaque (Becton Dickinson) density gradient centrifugation from anticoagulated venous blood samples, before flow cytometry. Alternatively, flow cytometry was performed on fresh whole blood samples. For confocal microscopy and cell culture studies, CD3 ϩ or CD3 ϩ CD4 ϩ cells were further enriched by Robosep using EasySep Negative selection Human CD3 ϩ or CD3 ϩ CD4 ϩ T cell enrichment kit and procedure (Voden).
TCR Expression Analysis
Surface staining of T cell subsets was performed by standard methods. For intracellular staining, cells were fixed with 2% formaldehyde and permeabilized in buffer containing 10 g/mL saponin.
The efficiency of permeabilization was determined by uptake of trypan blue (Ͼ99% in all experiments). Isotype-matched controls Abs were used to confirm expression specificity. The following Abs were purchased from Becton Dickinson: mouse IgG1 isotype control conjugated with PE (clone MOPC-21) or with fluorescein isothiocyanate (FITC) (cloneA85-1), anti-CD3-FITC (clone UCHT1), anti-CD4-PE-Cychrome 5 (clone RPA-T4), anti-CD8-Cychrome 5 (clone HIT8a), anti-CD3-PE-Cychrome 5 (clone HIT3a), anti-CD16-FITC (clone 3G8), anti-CD3-Pacific Blue (PB) (clone UCHT1), anti-FoxP3-PB (clone 206D). Two different antibodies were used for TCR, expression studies: anti-TCR-PE (clone 2H2D9, Immunotech, Coulter), anti-TCR-FITC (cloneG3,Dako). The 2 different clones used of anti-TCR individuate the same percentage of TCR dim cells. The CD3 -CD56 ϩ NK cell subset was found to be uniformly TCR negative, and was not therefore studied further.
We confirmed data also with fresh whole blood analysis (cell viability Ͼ99%). Cell viability was assessed using the Molecular Probes Patented LIVE/DEAD Viability (Invitrogen) according to the manufacturer instructions. Moreover, frequencies of TCR dim within the CD3 ϩ CD4 ϩ CD28 null subset were determined by a 4-color flow cytometry on fresh whole blood performed using anti-CD3-Cascade Yellow (clone UCHT1, Dako), anti-CD4-activated protein C (APC)- 
Confocal Microscopy
Cells from 10 subjects randomly chosen among ACS patients (nϭ3), CSA patients (nϭ2) and controls (nϭ5) were fixed and stained for confocal microscopy with anti-CD3-PB (clone UCHT1, Becton Dickinson) or anti-CD3-FITC (clone UCHT1, Becton Dickinson) and, on permeabilization, anti-TCR-FITC (clone G3, Dako) or anti-TCR-PE (clone 2H2D9, Immunotech, Coulter). Cells were subsequently plated onto glass slides and examined under a Leica TCS SP2 AOBS confocal microscope (Leica Microsystems). Z-series were collected from singles channels, processed to 2D free projection max images, and merged. Single stains either for CD3 and TCR served as controls.
Measurement of High Sensitivity CRP (hsCRP)
Peripheral blood samples were centrifuged and serum aliquots were stored at Ϫ80°C until assayed in single batch. hsCRP was assessed via nephelometry (BN II-Behring instrument).
Transendothelial Migration Assay
We performed transendothelial migration assays of T cells in 17 study subjects (5 controls, 6 CSA, and 6 ACS), by applying 10 6 lymphocytes to gelatin-coated transwell upper chambers containing a monolayer of human umbilical vein endothelial cells (HUVECs) previously stimulated with 10 ng/mL TNF-␣ for 48 hours. 15 After 24 hours at 37°C, T cells in the upper and lower chamber were recovered, and the numbers of migrating CD4 ϩ and CD8 ϩ TCR bright or TCR dim T cells were determined in each chamber by flow cytometry. Results are expressed as the percentage of cells migrating relative to the total number of each cell subset added to the transwell (TCR bright in the lower chamber at timeϭ24 hours/ TCR bright at timeϭ0 versus TCR dim in the lower chamber timeϭ24 hours/ TCR dim at timeϭ0).
Statistical Analysis
The datasets did not conform to a normal distribution. MannWhitney U test and Kruskall-Wallis test with Dunn multiple comparison test were used as appropriate. Wilcoxon matched paired test was used for repeated measures in the time. Spearman rank test was used to test correlations between variables. GraphPad Prism 4 and GraphPad Instat 3 softwares were used for analysis. A probability value Ͻ0.05 was considered significant.
Results
Characteristics of Patients
No significant differences in demographic and risk factors were observed between CSA group and ACS group (Table) . However, differences were found in therapeutic regimens at the time of the sampling. Such differences were likely attributable to the fact that for 80% of patients in the ACS group, this hospital admission represented their first clinical manifestation of coronary disease versus only 56% in the CSA group (Pϭ0.02). However, at 50-day follow-up there were no statistical differences regarding therapy between the two groups (PϭNS; data not shown). ACS samples were obtained very early after the onset of symptoms when the elevation of troponin I were still minimal (0.4Ϯ0.0 to 5.9 ng/mL), thus ruling out the possible confounding effect of myocardial necrosis. The extent of coronary atherosclerosis was similar in patients in CSA and ACS group as documented by the number of diseased vessels in CSA, 2.0Ϯ0.8 (expressed as meanϮSD), compared to ACS, 1.9Ϯ0.9 (Pϭ0.79).
Substantial Downregulation of the TCR-Chain in CD4 ؉ in ACS
Flow cytometric analysis (see representative dot-plots and histograms in Figure 1A through 1G) revealed a 3-fold increase in the percentage of CD3 ϩ TCR dim T cells in ACS patients (median; interquartile range: 8.2%; 3.8 to 14.5%, PϽ0.0001; supplemental Table I , available online at http:// atvb.ahajournals.org) compared to controls (2.6; 1.1 to 5.3%) and CSA (3.1; 1.7 to 7.0%). Confocal microscopy images confirmed the presence of CD3 ϩ cells with downregulation of the expression of TCR-chain in patients with ACS ( Figure  1H through 1J and supplemental Figures I and II). Circulating CD4 ϩ TCR dim T cells showed a 3-fold increase in patients with ACS (5.3%; 2.6 to 9.1%; PϽ0.0001, Figure 2A ) when compared to controls (1.5; 0.5 to 2.9%) and CSA (1.6; 1.0 to 4.1%). The MFI index of TCR-chain was significantly reduced in patients with ACS in comparison to controls and patients with CSA (supplemental Figure III) . To exclude that the increased levels of TCR dim T cells reported in ACS were merely attributable to cell death, we showed that cell viability in CD3 ϩ T cells were Ͼ99% out of total CD3 ϩ in fresh blood, and that TCR dim T cells were not confined to the non viable cells (supplemental Figure IV) . Differences in statin therapy are unlikely to explain the differences in TCR expression, as a subgroup analysis in patients without statin therapy (ACS nϭ54; CSA nϭ14) confirmed a significant increase of CD4 ϩ TCR dim T cells in ACS (Pϭ0.002). Moreover, statin treatment itself was unlikely to provoke such changes as by comparing CSA patients with (nϭ18) or without (nϭ14) statin therapy (respectively 1.3; 0.9 to 3.7% versus 1.8; 0.9 to 5.1%; Pϭ0.46) no significant differences were found.
Downregulation of TCR-Chain in CD8
؉ and NK
Cells in ACS
We further assessed that downregulation of TCR-chain was not limited to CD4 ϩ T cells in ACS. Indeed TCR dim T cells represented 4.0% (2 to 5.7%) of peripheral circulating CD8 ϩ T cells in patients with ACS in comparison to 0.6% (0.2 to 1.9%) in controls, and 1.2% (0.8 to 2.1%) in patients with CSA (PϽ0.0001; supplemental Figure VA) . Also, a 2-fold increase was observed in the levels of TCR dim within the circulating CD3 -CD16 ϩ NK cell subset (5.1%; 2.4 to 7.5%) in patients with ACS, whereas they accounted for 2.5% (1.3 to 3.8%) and 1.6% (0.9 to 2.7%) in controls and in patients with CSA respectively (Pϭ 0.001; supplemental Figure VB) . No significant differences were observed between control individuals and CSA patients for either T-cell or NK-cell subsets.
Persistence of Circulating CD4
؉ TCR dim T Cells in ACS Patients at Follow-Up
Frequencies of circulating CD4
ϩ TCR dim T cells were unchanged at a 50-day follow-up after admission (6.4; 3.7 to 10.5% versus 5.5; 3.2 to 7.7%; Pϭ0.95; Figure 2D ), despite antiischemic therapy and risk factor management.
Increased Frequencies of TCR dim T Cells Are Associated With Higher CRP Levels
We observed that the frequency of CD4 . Considering a cut-off of CRP Ն2 mg/L used in previous studies, 20 patients with ACS and CRP levels Ն2 mg/L had significantly increased percentages of CD4 ϩ TCR dim T cells (7.7; 3.8 to 11.3%, Pϭ0.003, nϭ41) compared to patients with ACS and low CRP levels Ͻ2 mg/L (3.3; 1.7 to 7.7%, nϭ25; Figure 3 ).
Reduction of TCR-Chain in CD4
؉ CD28 null T Cells in Patients With ACS In 60 subjects, blood samples were simultaneously stained for CD3, CD4, CD28, and TCR and analyzed by 4-color flow cytometry. We observed a significant correlation between frequencies of CD4 ϩ CD28 null T cells and CD4 ϩ TCR dim T cells (rϭ0.43; Pϭ0.0006; Figure 4A ), especially within ACS patients (rϭ0.62; Pϭ0.002; supplemental Figure VIIA) . Interestingly, a reduction of TCR-chain expression was ob- 
Discussion
We report for the first time expansion of circulating T cells expressing reduced levels of the invariant TCR-chain in patients with ACS compared to patients with CSA and controls. CD4
ϩ TCR dim T cells remained elevated for at least 50 days after the acute event. In addition, we also documented that TCR-chain downregulation was not limited to T cell subpopulations, but was also present in NK cells. Enrichment of TCR dim cells correlated with the magnitude of the systemic inflammatory response, raising the possibility that TCR dim cells might participate to the ongoing inflammatory and immune response in ACS.
Functional Aspects of TCR dim T Cells in Coronary Artery Disease
Growing similarities are emerging between atherosclerosis and chronic inflammatory diseases, including the expansion of circulating and lesional effector cells such as T-lymphocyte subsets. 10 Despite T cells with low levels of TCR-chain expression being refractory to TCR signaling, 19 we have recently reported that TCR dim T cells express the hallmarks of memory antigen experienced effector T cells, 15 produce abundant inflammatory cytokines such as TNF␣ and IFN␥, and promote monocyte activation through cell contact dependent pathways. 15 Moreover, TCR dim T cells do not produce antiinflammatory cytokine such as IL-10, 15 and do not express the T regulatory cell marker Forkhead Box Protein P3 (FoxP3; supplemental Figure X ). Collectively these observations point toward the requirement for intact TCR signaling to maintain immune homeostasis through the generation or function of regulatory T cell subsets. 21 Furthermore, in this study we also observed that also in patients with CAD the ability of circulating TCR dim T cells to migrate through endothelium is enhanced compared to their TCR bright counterparts. In previous study we showed also enhanced chemotactic migratory ability of TCR dim T cells in response to chemokines, such as CCL5 and CXCL10. 15 Consistent with these in vitro observations, we previously documented that TCR dim T cells are enriched in synovial fluid and tissue from patients with rheumatoid arthritis. 15 Moreover, in 3 patients with ACS enrolled in the study we documented a decrease in the number of CD3 ϩ
CD4
ϩ TCR dim T cells in blood acquired from the great cardiac vein before angioplasty compared to levels of CD3 ϩ
ϩ TCR dim T cells sampled from the aorta 5 (supplemental Figure XI) . These results could suggest an accumulation of this cell population in the coronary circulation during the acute phase of the disease. Thus, antigen experienced effector TCR dim T cells with enhanced migratory competence have the potential to extravasate and exert local proinflammatory actions in atherosclerotic plaques, thus contributing to plaque destabilization.
Possible Mechanisms of TCR-Chain Downregulation
In our study the enrichment of circulating CD4
ϩ TCR dim T cell in patients with ACS was associated with higher levels of hsCRP, suggesting that the inflammatory milieu in patients with ACS may contribute to TCR-chain downregulation. Antigen-dependent and antigen-independent mechanisms have been advocated to explain downregulation of the TCRchain in human and experimental models. 14 Both mechanisms may have a role in TCR-chain downregulation in ACS. For instance, prolonged exposure to bacterial and viral antigens has been shown to induce TCR-chain down-regulation in vivo. 14 In the setting of ACS, a variety of infectious and endogenous antigen(s) have been implicated (ie, modified low-density lipoprotein, endogenous and infectious agentsderived heat shock proteins) and could potentially lead to TCR-chain downregulation. [22] [23] [24] Antigen-independent mechanisms, eg, prolonged exposure inflammatory cytokines including IFN␥ and TNF␣, as well as reactive oxygen intermediates, have also been advocated for TCR-chain downregulation. 19 In our study, the downregulation of the TCR-chain was not limited to CD4 ϩ and CD8 ϩ T cells but was also present in the NK-cell population, in which it may arise through FcR engagement, perhaps via immune complexes or through cytokine stimulation. 14 Interestingly, the loss of CD28, as the downregulation of TCR-chain, has been linked to both chronic antigen or cytokine exposure. 19, 25, 26 CD4   ϩ   CD28 null T cells, a terminally differentiated effector T cell population, was identified both in patients with rheumatoid arthritis with vascular complications and in patients with ACS. 12, 13, 27 More then 65% of CD4 ϩ
CD28
null T cells from patients with ACS had selectively reduced TCRchain expression. Hence, in the context of ACS, similar mechanisms might explain the reduced TCR-chain expression and the loss of CD28, and the generation of T-cell subsets with perturbation of the classical immunologic synapse. 
Conclusion
We show that circulating TCR dim cells are increased in ACS, and such increase is associated with higher levels of hsCRP. TCR dim cells display an increased ability to cross activated endothelium, and might carry the potential to accumulate in atherosclerotic plaques. Both antigen-dependent and antigenindependent mechanisms may contribute to the emergence of this unusual T-cell surface phenotype. The aberrant expression of TCR-chain in circulating cell subsets further supports the role of dysregulation of the immune response in the pathogenesis of ACS. Moreover, our findings may contribute to explain the increased incidence of major cardiovascular events in systemic lupus erythematosus and rheumatoid arthritis. 28 Expansion of TCRζ 
